Clareo Health | A Study of Duration of Maintained Efficacy in Rheumatoid Arthritis (RA) Patients Off Treatment With MRA(a Development Code of Tocilizumab, an Anti IL-6 Receptor Monoclonal Antibody.)
A Study of Duration of Maintained Efficacy in Rheumatoid Arthritis (RA) Patients Off Treatment With MRA(a Development Code of Tocilizumab, an Anti IL-6 Receptor Monoclonal Antibody.)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Chugai Pharmaceutical
Age
20–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients who achieved DAS28 of \< 3.2 at the last observation and at least one time point among the two previous assessment time points in a previous studies.
You may not be if
Patients who receive DMARDs or immunosuppressants between the last observation in a previous studies and the first observation in this study
